TABLE 4.
Inhibitory activity of lipopeptide fusion inhibitors on HIV-1 Env-mediated cell-cell fusiona
| Env | Subtype | Mean IC50 ± SD (pM) for: |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| T20 | LP-52 | LP-80 | LP-83 | LP-86 | LP-93 | LP-94 | LP-95 | C34-Chol | ||
| 92RW020 | A | 788.87 ± 39.86 | 159.53 ± 15.81 | 5.07 ± 0.53 | 6.4 ± 1 | 7.78 ± 0.9 | 12.19 ± 2.43 | 16.24 ± 3.61 | 18.1 ± 2.56 | 44.11 ± 9.17 |
| PVO | B | 6,268.67 ± 1,763.06 | 129.1 ± 19.93 | 9.52 ± 2.22 | 5.27 ± 0.72 | 7.6 ± 1.06 | 8.3 ± 1.01 | 17.14 ± 2.26 | 16.42 ± 5.11 | 47.21 ± 9.06 |
| B02 | B' | 14,783.33 ± 1,955.25 | 47.63 ± 4.8 | 26.15 ± 2.89 | 10.07 ± 1.41 | 18.11 ± 1.57 | 26.16 ± 5.99 | 30.65 ± 3.81 | 54.18 ± 9.6 | 243.77 ± 35.87 |
| CAP210.2.00.E8 | C | 4,311.67 ± 518.8 | 21.08 ± 1.93 | 15.04 ± 2.63 | 6.61 ± 0.89 | 8 ± 0.85 | 12.17 ± 1.67 | 16.44 ± 1.95 | 18.24 ± 1.78 | 142.3 ± 33.46 |
| X1632-S2-B10 | G | 10,708 ± 1,666.1 | 21.17 ± 8.85 | 7.6 ± 1.05 | 4.67 ± 1.11 | 4.02 ± 1.29 | 9.53 ± 2.23 | 8.45 ± 2.88 | 25.16 ± 5.68 | 153.97 ± 36.72 |
| 246F3 | A/C | 11,330 ± 1,156.26 | 5.05 ± 0.7 | 9.78 ± 0.94 | 4.53 ± 0.77 | 6.1 ± 1.54 | 10.37 ± 0.9 | 11.11 ± 1.93 | 13.72 ± 2.63 | 97.5 ± 4.86 |
| GX11.13 | A/E | 9,439 ± 2,593.64 | 42.34 ± 2.2 | 20.45 ± 2.55 | 14.35 ± 1.01 | 22.99 ± 1.78 | 16.22 ± 1.77 | 51.96 ± 14.35 | 31.89 ± 3.91 | 229.9 ± 10.34 |
| CH120.6 | B/C | 11,422 ± 2,323.97 | 27.45 ± 4.69 | 13.57 ± 3.07 | 16.47 ± 3.05 | 23.59 ± 5.82 | 21.15 ± 1.68 | 66.9 ± 3.61 | 61.03 ± 9.05 | 190.1 ± 66.12 |
| Mean | 8,631.44 | 56.67 | 13.4 | 8.55 | 12.27 | 14.51 | 27.36 | 29.84 | 143.61 | |
a
The assay was performed in triplicates and repeated three times.